Herz Life
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Herz Life - overview
Established
2020
Location
Shenzhen, Guangdong, China
Primary Industry
Biotechnology
About
Established in 2020 and based in Shenzhen, China, Shenzhen Herz Life Science Technology Co. , Ltd. , trading as Herz Life, is a developer that focuses on pet vaccines based on virus-like particle VLPs technology. In January 2026, Herz Life raised a series B funding from new investors Hainan Zhenmai Private Equity Fund Management, Real Power Capital, Tiantu Capital, and Shida Group.
Herz Life Science engages in the development of animal and human vaccines. Its main products include feline transabdominal vaccine and castration vaccine. The company generates revenue from providing its pet vaccine products. The company generates revenue from providing its pet vaccine products.
Current Investors
Triwise Capital, Cowin Capital, Shenzhen HTI
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.hzlifetech.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.